Weijia Fang
- Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis 15
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers 40
- Colorectal Cancer Treatments and Studies 27
- Pancreatic and Hepatic Oncology Research 17
- CAR-T cell therapy research 16
- Cancer Research top 5%
- Cancer Genomics and Diagnostics 13
- Immunology top 5%
- Immune Cell Function and Interaction 10
-
- Gastric Cancer Management and Outcomes 13
- Co-authors
- Shuiguang DengHailiang ZhaoJianwei YinSchahram DustdarAlbert Y. ZomayaPeng ZhaoYi ZhengHangyu Zhang
- Cited by
- HepatologyOncologyCancer Research
- Journals
- Cell (1 paper)Journal of Clinical Oncology (23 papers)SHILAP Revista de lepidopterología (1 paper)
- Partner nations
- ChinaUnited StatesTaiwan
In The Last Decade
Weijia Fang
130 papers receiving 4.1k citations
Hit Papers
Peers
Comparison fields: 5 of 160
- Hepatology 748
- Oncology 1.7k
- Cancer Research 472
- Immunology 592
- Pulmonary and Respiratory Medicine 715
Countries citing papers authored by Weijia Fang
This map shows the geographic impact of Weijia Fang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weijia Fang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weijia Fang more than expected).
Fields of papers citing papers by Weijia Fang
This network shows the impact of papers produced by Weijia Fang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weijia Fang. The network helps show where Weijia Fang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Weijia Fang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 3 | |
| 2 | 2024 | 35 | |
| 3 | 2024 | 10 | |
| 4 | 2024 | 5 | |
| 5 | 2024 | 8 | |
| 6 | Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironmentbreakdown → | 2024 | 68 |
| 7 | 2023 | 3 | |
| 8 | 2023 | 4 | |
| 9 | 2023 | 46 | |
| 10 | Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trialbreakdown → | 2022 | 127 |
| 11 | 2022 | 8 | |
| 12 | 2022 | 58 | |
| 13 | 2022 | 7 | |
| 14 | 2021 | 6 | |
| 15 | 2021 | 10 | |
| 16 | 2021 | 36 | |
| 17 | Edge Intelligence: The Confluence of Edge Computing and Artificial Intelligencebreakdown → | 2020 | 655 |
| 18 | 2020 | 99 | |
| 19 | Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinomabreakdown → | 2019 | 392 |
| 20 | 2017 | 21 |
About Weijia Fang
Weijia Fang is a scholar working on Oncology, Hepatology and Immunology, having authored 139 papers that have together received 4.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (40 papers), Colorectal Cancer Treatments and Studies (27 papers), Pancreatic and Hepatic Oncology Research (17 papers), CAR-T cell therapy research (16 papers), Hepatocellular Carcinoma Treatment and Prognosis (15 papers), Cancer Genomics and Diagnostics (13 papers), Gastric Cancer Management and Outcomes (13 papers) and Immune Cell Function and Interaction (10 papers). The work is most often cited by research in Hepatology (748 citations), Oncology (1.7k citations) and Cancer Research (472 citations). Weijia Fang has collaborated with scholars based in China, United States and Taiwan. Frequent co-authors include Shuiguang Deng, Hailiang Zhao, Jianwei Yin, Schahram Dustdar, Albert Y. Zomaya, Peng Zhao, Yi Zheng, Hangyu Zhang, Weiqin Jiang and Zhou Tong. Their work appears in journals such as Cell, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.